{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:38:39Z","timestamp":1792809519409,"version":"4.5.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40123-026-01493-z","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T07:58:12Z","timestamp":1789804692000},"page":"3589-3601","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing the Ocular Surface Before, During, and After Glaucoma Surgery: A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Antoine","family":"Labb\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Tatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingeborg","family":"Stalmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Baudouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"issue":"1","key":"1493_CR1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.5301\/ejo.5000181","volume":"23","author":"C Baudouin","year":"2012","unstructured":"Baudouin C, Renard J-P, Nordmann J-P, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2012;23(1):47\u201354.","journal-title":"Eur J Ophthalmol."},{"key":"1493_CR2","volume":"2013","author":"S Ka\u0161telan","year":"2013","unstructured":"Ka\u0161telan S, Tomi\u0107 M, Mete\u017e Soldo K, Salopek-Rabati\u0107 J. How ocular surface disease impacts the glaucoma treatment outcome. BioMed Res Int. 2013;2013:696328.","journal-title":"BioMed Res Int."},{"issue":"10180","key":"1493_CR3","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(18)32213-X","volume":"393","author":"G Gazzard","year":"2019","unstructured":"Gazzard G, Konstantakopoulou E, Garway-Heath D, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. Lancet. 2019;393(10180):1505\u201316.","journal-title":"Lancet"},{"issue":"9","key":"1493_CR4","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.ophtha.2019.04.012","volume":"126","author":"A Garg","year":"2019","unstructured":"Garg A, Vickerstaff V, Nathwani N, et al. Primary selective laser trabeculoplasty for open-angle glaucoma and ocular hypertension: clinical outcomes, predictors of success, and safety from the laser in glaucoma and ocular hypertension trial. Ophthalmology. 2019;126(9):1238\u201348.","journal-title":"Ophthalmology."},{"key":"1493_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12010151","author":"B Cvenkel","year":"2022","unstructured":"Cvenkel B, Kolko M. Devices and treatments to address low adherence in glaucoma patients: a narrative review. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm12010151.","journal-title":"J Clin Med"},{"issue":"10","key":"1493_CR6","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/IJG.0000000000002465","volume":"33","author":"EM Messmer","year":"2024","unstructured":"Messmer EM, Baudouin C, Benitez-Del-Castillo J-M, et al. Expert consensus recommendations for the management of ocular surface inflammation in patients with glaucoma. J Glaucoma. 2024;33(10):715\u201327.","journal-title":"J Glaucoma"},{"issue":"9","key":"1493_CR7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/jop.2024.0029","volume":"40","author":"J Bacharach","year":"2024","unstructured":"Bacharach J, McLaurin EB, Silverstein S, et al. Efficacy and safety of a preservative-free latanoprost cationic emulsion in patients with open-angle glaucoma and concurrent ocular surface disease: a randomized phase 2 study. J Ocul Pharmacol Ther. 2024;40(9):553\u201361.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"12","key":"1493_CR8","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1097\/IJG.0000000000001659","volume":"29","author":"A Muzychuk","year":"2020","unstructured":"Muzychuk A, Racine L, Robert M-C, et al. Management of ocular surface disease in glaucoma: a survey of Canadian glaucoma specialists. J Glaucoma. 2020;29(12):1162\u201372.","journal-title":"J Glaucoma"},{"issue":"Suppl 1","key":"1493_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bjophthalmol-2025-egsguidelines","volume":"109","author":"M Pazos","year":"2025","unstructured":"Pazos M, Traverso CE, Viswanathan A. European Glaucoma Society - terminology and guidelines for glaucoma, 6th Edition. Br J Ophthalmol. 2025;109(Suppl 1):1\u2013212.","journal-title":"Br J Ophthalmol"},{"key":"1493_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030657","author":"CG Shao","year":"2023","unstructured":"Shao CG, Sinha NR, Mohan RR, Webel AD. Novel therapies for the prevention of fibrosis in glaucoma filtration surgery. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11030657.","journal-title":"Biomedicines"},{"issue":"7","key":"1493_CR11","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/aos.15098","volume":"100","author":"L Agnifili","year":"2022","unstructured":"Agnifili L, Sacchi M, Figus M, et al. Preparing the ocular surface for glaucoma filtration surgery: an unmet clinical need. Acta Ophthalmol. 2022;100(7):740\u201351.","journal-title":"Acta Ophthalmol"},{"issue":"Pt 4","key":"1493_CR12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/eye.1993.108","volume":"7","author":"DC Broadway","year":"1993","unstructured":"Broadway DC, Bates AK, Lightman SL, Grierson I, Hitchings RA. The importance of cellular changes in the conjunctiva of patients with uveitic glaucoma undergoing trabeculectomy. Eye (London, England). 1993;7(Pt 4):495\u2013501.","journal-title":"Eye (London, England)"},{"issue":"9","key":"1493_CR13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/IJG.0b013e31825af67d","volume":"22","author":"C Boimer","year":"2013","unstructured":"Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013;22(9):730\u20135.","journal-title":"J Glaucoma."},{"issue":"3","key":"1493_CR14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archopht.1996.01100130258004","volume":"114","author":"DC Broadway","year":"1996","unstructured":"Broadway DC, Grierson I, St\u00fcrmer J, Hitchings RA. Reversal of topical antiglaucoma medication effects on the conjunctiva. Arch Ophthalmol (Chicago, Ill: 1960). 1996;114(3):262\u20137.","journal-title":"Arch Ophthalmol (Chicago, Ill.: 1960)."},{"issue":"7","key":"1493_CR15","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.ophtha.2009.11.038","volume":"117","author":"C Breusegem","year":"2010","unstructured":"Breusegem C, Spielberg L, van Ginderdeuren R, et al. Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmology. 2010;117(7):1324\u201330.","journal-title":"Ophthalmology."},{"issue":"7","key":"1493_CR16","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s00417-023-06333-5","volume":"262","author":"L Agnifili","year":"2024","unstructured":"Agnifili L, Figus M, Sacchi M, et al. Managing the ocular surface after glaucoma filtration surgery: an orphan topic. Graefes Arch Clin Exp Ophthalmol. 2024;262(7):2039\u201356.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"1493_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/11206721231199157","author":"M Figus","year":"2023","unstructured":"Figus M, Sacchi M, Rossi GC, et al. Ocular surface and glaucoma, a mutual relationship. Practical suggestions for classification and management. Eur J Ophthalmol. 2023. https:\/\/doi.org\/10.1177\/11206721231199157.","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"1493_CR18","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/aos.14881","volume":"100","author":"B Kudsieh","year":"2022","unstructured":"Kudsieh B, Fern\u00e1ndez-Vigo JI, Canut Jordana MI, et al. Updates on the utility of anterior segment optical coherence tomography in the assessment of filtration blebs after glaucoma surgery. Acta Ophthalmol. 2022;100(1):e29\u201337.","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"1493_CR19","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.ophtha.2005.05.021","volume":"112","author":"A Labb\u00e9","year":"2005","unstructured":"Labb\u00e9 A, Dupas B, Hamard P, Baudouin C. In vivo confocal microscopy study of blebs after filtering surgery. Ophthalmology. 2005;112(11):1979.","journal-title":"Ophthalmology."},{"issue":"8","key":"1493_CR20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1001\/archopht.124.8.1095","volume":"124","author":"EM Messmer","year":"2006","unstructured":"Messmer EM, Zapp DM, Mackert MJ, Thiel M, Kampik A. In vivo confocal microscopy of filtering blebs after trabeculectomy. Arch Ophthalmol (Chicago, Ill: 1960). 2006;124(8):1095\u2013103.","journal-title":"Arch Ophthalmol (Chicago, Ill.: 1960)."},{"issue":"4","key":"1493_CR21","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1097\/IJG.0000000000000377","volume":"25","author":"C Caglar","year":"2016","unstructured":"Caglar C, Karpuzoglu N, Batur M, Yasar T. In vivo confocal microscopy and biomicroscopy of filtering blebs after trabeculectomy. J Glaucoma. 2016;25(4):e377-83.","journal-title":"J Glaucoma"},{"issue":"7","key":"1493_CR22","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ophtha.2007.10.024","volume":"115","author":"N Amar","year":"2008","unstructured":"Amar N, Labb\u00e9 A, Hamard P, Dupas B, Baudouin C. Filtering blebs and aqueous pathway an immunocytological and in vivo confocal microscopy study. Ophthalmology. 2008;115(7):1154-1161.e4.","journal-title":"Ophthalmology."},{"issue":"11","key":"1493_CR23","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/bjo.2006.094912","volume":"90","author":"M Souchier","year":"2006","unstructured":"Souchier M, Buron N, Lafontaine PO, Bron AM, Baudouin C, Creuzot-Garcher C. Trefoil factor family 1, MUC5AC and human leucocyte antigen-DR expression by conjunctival cells in patients with glaucoma treated with chronic drugs: could these markers predict the success of glaucoma surgery? Br J Ophthalmol. 2006;90(11):1366\u20139.","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"1493_CR24","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1167\/iovs.16-19257","volume":"57","author":"L Agnifili","year":"2016","unstructured":"Agnifili L, Fasanella V, Mastropasqua R, et al. In vivo goblet cell density as a potential indicator of glaucoma filtration surgery outcome. Invest Ophthalmol Vis Sci. 2016;57(7):2928\u201335.","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"1493_CR25","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100916","volume":"83","author":"C Baudouin","year":"2021","unstructured":"Baudouin C, Kolko M, Melik-Parsadaniantz S, Messmer EM. Inflammation in glaucoma: from the back to the front of the eye, and beyond. Prog Retin Eye Res. 2021;83:100916.","journal-title":"Prog Retin Eye Res"},{"issue":"4","key":"1493_CR26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/tvst.8.4.4","volume":"8","author":"S Hayek","year":"2019","unstructured":"Hayek S, Labb\u00e9 A, Brasnu E, Hamard P, Baudouin C. Optical coherence tomography angiography evaluation of conjunctival vessels during filtering surgery. Transl Vis Sci Technol. 2019;8(4):4.","journal-title":"Transl Vis Sci Technol."},{"key":"1493_CR27","doi-asserted-by":"crossref","unstructured":"Lee JY, Heilweil G, Le P, et al. Structural confirmation of lymphatic outflow from subconjunctival blebs of live human subjects. Ophthalmol Sci. 2021;1(4).","DOI":"10.1016\/j.xops.2021.100080"},{"key":"1493_CR28","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108049","volume":"196","author":"G Akiyama","year":"2020","unstructured":"Akiyama G, Saraswathy S, Bogarin T, et al. Functional, structural, and molecular identification of lymphatic outflow from subconjunctival blebs. Exp Eye Res. 2020;196:108049.","journal-title":"Exp Eye Res"},{"key":"1493_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052327","author":"M Sacchi","year":"2025","unstructured":"Sacchi M, Tomaselli D, Ruggeri ML, et al. Fighting bleb fibrosis after glaucoma surgery: updated focus on key players and novel targets for therapy. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26052327.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"1493_CR30","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.preteyeres.2009.06.004","volume":"28","author":"D-Y Yu","year":"2009","unstructured":"Yu D-Y, Morgan WH, Sun X, et al. The critical role of the conjunctiva in glaucoma filtration surgery. Prog Retin Eye Res. 2009;28(5):303\u201328.","journal-title":"Prog Retin Eye Res"},{"key":"1493_CR31","doi-asserted-by":"crossref","unstructured":"Mastropasqua L, Brescia L, D'Arcangelo F, et al. Topical steroids and glaucoma filtration surgery outcomes: an in vivo confocal study of the conjunctiva. J Clin Med. 2022;11(14).","DOI":"10.3390\/jcm11143959"},{"key":"1493_CR32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ajo.2025.05.033","volume":"279","author":"JS Wolffsohn","year":"2025","unstructured":"Wolffsohn JS, Ben\u00edtez-Del-Castillo JM, Loya-Garcia D, et al. TFOS DEWS III: diagnostic methodology. Am J Ophthalmol. 2025;279:387\u2013450.","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"1493_CR33","doi-asserted-by":"crossref","first-page":"P50","DOI":"10.1016\/j.ophtha.2023.12.036","volume":"131","author":"A Lin","year":"2024","unstructured":"Lin A, Ahmad S, Amescua G, et al. Blepharitis preferred practice pattern\u00ae. Ophthalmology. 2024;131(4):P50\u201386.","journal-title":"Ophthalmology"},{"issue":"11","key":"1493_CR34","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.ophtha.2013.03.045","volume":"120","author":"PM Mathews","year":"2013","unstructured":"Mathews PM, Ramulu PY, Friedman DS, Utine CA, Akpek EK. Evaluation of ocular surface disease in patients with glaucoma. Ophthalmology. 2013;120(11):2241\u20138.","journal-title":"Ophthalmology"},{"issue":"5","key":"1493_CR35","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/11206721231222939","volume":"34","author":"C Baudouin","year":"2024","unstructured":"Baudouin C, Misiuk-Hojlo M, Benitez-Del-Castillo-Sanchez JM, et al. FAST\u00ae questionnaire for identifying glaucoma patients at risk for ocular surface disease. Eur J Ophthalmol. 2024;34(5):1443\u20139.","journal-title":"Eur J Ophthalmol"},{"key":"1493_CR36","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jtos.2023.05.012","volume":"29","author":"M Kolko","year":"2023","unstructured":"Kolko M, Gazzard G, Baudouin C, et al. Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment. Ocul Surf. 2023;29:456\u201368.","journal-title":"Ocul Surf"},{"issue":"12","key":"1493_CR37","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/IJG.0000000000001041","volume":"27","author":"P Dubrulle","year":"2018","unstructured":"Dubrulle P, Labb\u00e9 A, Brasnu E, et al. Influence of treating ocular surface disease on intraocular pressure in glaucoma patients intolerant to their topical treatments: a report of 10 cases. J Glaucoma. 2018;27(12):1105\u201311.","journal-title":"J Glaucoma"},{"issue":"2","key":"1493_CR38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000517845","volume":"6","author":"A Hedengran","year":"2021","unstructured":"Hedengran A, Begun X, M\u00fcllertz O, et al. Benzalkonium chloride-preserved anti-glaucomatous eye drops and their effect on human conjunctival goblet cells in vitro. Biomed Hub. 2021;6(2):69\u201375.","journal-title":"Biomed Hub"},{"issue":"4","key":"1493_CR39","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin C, Labb\u00e9 A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312\u201334.","journal-title":"Prog Retin Eye Res"},{"key":"1493_CR40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ajo.2025.05.039","volume":"279","author":"L Jones","year":"2025","unstructured":"Jones L, Craig JP, Markoulli M, et al. TFOS DEWS III: management and therapy. Am J Ophthalmol. 2025;279:289\u2013386.","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"1493_CR41","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1111\/aos.12131","volume":"91","author":"L Mastropasqua","year":"2013","unstructured":"Mastropasqua L, Agnifili L, Fasanella V, et al. Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study. Acta Ophthalmol. 2013;91(5):e397-405.","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"1493_CR42","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1177\/11206721221141481","volume":"33","author":"EM Messmer","year":"2023","unstructured":"Messmer EM, Ahmad S, Benitez Del Castillo JM, et al. Management of inflammation in dry eye disease: recommendations from a European panel of experts. Eur J Ophthalmol. 2023;33(3):1294\u2013307.","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"1493_CR43","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s12325-019-01137-8","volume":"37","author":"M Kallab","year":"2020","unstructured":"Kallab M, Szegedi S, Hommer N, et al. Topical low-dose preservative-free hydrocortisone reduces signs and symptoms in patients with chronic dry eye: a randomized clinical trial. Adv Ther. 2020;37(1):329\u201341.","journal-title":"Adv Ther"},{"key":"1493_CR44","unstructured":"Rousseau A. Be aware of glaucoma therapy-related ocular surface disease when planning filtration surgery! https:\/\/eugs.org\/news\/be-aware-of-glaucoma-therapy-related-ocular-surface-disease-when-planning-filtration-surgery-2022-03-31-tip-of-the-month. 2022;Viewed 06-Feb-2026."},{"key":"1493_CR45","unstructured":"Eberhardt M, Zeppieri M, Rammohan G. Blepharitis. In: StatPearls. Treasure Island (FL); 2025."},{"key":"1493_CR46","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2147\/OPTH.S48745","volume":"8","author":"T van Bergen","year":"2014","unstructured":"van Bergen T, van de Velde S, Vandewalle E, Moons L, Stalmans I. Improving patient outcomes following glaucoma surgery: state of the art and future perspectives. Clin Ophthalmol (Auckland, NZ). 2014;8:857\u201367.","journal-title":"Clin Ophthalmol (Auckland, N.Z.)."},{"issue":"4","key":"1493_CR47","first-page":"580","volume":"26","author":"MS Shapiro","year":"1985","unstructured":"Shapiro MS, Thoft RA, Friend J, Parrish RK, Gressel MG. 5-Fluorouracil toxicity to the ocular surface epithelium. Invest Ophthalmol Vis Sci. 1985;26(4):580\u20133.","journal-title":"Invest Ophthalmol Vis Sci."},{"issue":"3","key":"1493_CR48","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0039-6257(03)00038-9","volume":"48","author":"PJ Lama","year":"2003","unstructured":"Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Surv Ophthalmol. 2003;48(3):314\u201346.","journal-title":"Surv Ophthalmol"},{"issue":"Suppl 1","key":"1493_CR49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/bjophthalmol-2023-egsguidelines","volume":"107","author":"L Abegao Pinto","year":"2023","unstructured":"Abegao Pinto L, Sunaric M\u00e9gevand G, Stalmans I, et al. European Glaucoma Society\u2014a guide on surgical innovation for glaucoma. Br J Ophthalmol. 2023;107(Suppl 1):1\u2013114.","journal-title":"Br J Ophthalmol."},{"key":"1493_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering11050446","author":"B Dave","year":"2024","unstructured":"Dave B, Patel M, Suresh S, et al. Wound modulations in glaucoma surgery: a systematic review. Bioengineering (Basel). 2024. https:\/\/doi.org\/10.3390\/bioengineering11050446.","journal-title":"Bioengineering (Basel)"},{"issue":"3","key":"1493_CR51","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/IJG.0000000000001438","volume":"29","author":"DS Grover","year":"2020","unstructured":"Grover DS, Kornmann HL, Fellman RL. Historical considerations and innovations in the perioperative use of mitomycin C for glaucoma filtration surgery and bleb revisions. J Glaucoma. 2020;29(3):226\u201335.","journal-title":"J Glaucoma"},{"issue":"11","key":"1493_CR52","doi-asserted-by":"crossref","first-page":"CD006259","DOI":"10.1002\/14651858.CD006259.pub2","volume":"2015","author":"E Cabourne","year":"2015","unstructured":"Cabourne E, Clarke JCK, Schlottmann PG, Evans JR. Mitomycin C versus 5-Fluorouracil for wound healing in glaucoma surgery. Cochrane Database System Rev. 2015;2015(11):CD006259.","journal-title":"Cochrane Database System Rev."},{"key":"1493_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010059","author":"BR Seol","year":"2020","unstructured":"Seol BR, Lee SY, Kim YJ, Kim YK, Jeoung JW, Park KH. Comparison of the efficacy and safety of trabeculectomy with mitomycin C according to concentration: a prospective randomized clinical trial. J Clin Med. 2020. https:\/\/doi.org\/10.3390\/jcm10010059.","journal-title":"J Clin Med"},{"issue":"4","key":"1493_CR54","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s10384-014-0324-6","volume":"58","author":"H Sagara","year":"2014","unstructured":"Sagara H, Sekiryu T, Noji H, Ogasawara M, Sugano Y, Horikiri H. Meibomian gland loss due to trabeculectomy. Jpn J Ophthalmol. 2014;58(4):334\u201341.","journal-title":"Jpn J Ophthalmol"},{"key":"1493_CR55","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ajo.2020.03.002","volume":"216","author":"MC Lim","year":"2020","unstructured":"Lim MC, Hom B, Watnik MR, et al. A comparison of trabeculectomy surgery outcomes with mitomycin-C applied by intra-tenon injection versus sponge. Am J Ophthalmol. 2020;216:243\u201356.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"1493_CR56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ogla.2021.05.006","volume":"5","author":"SA Kandarakis","year":"2022","unstructured":"Kandarakis SA, Papakonstantinou E, Petrou P, et al. One-year randomized comparison of safety and efficacy of trabeculectomy with mitomycin C sub-tenon injection versus mitomycin C-infused sponges. Ophthalmol Glaucoma. 2022;5(1):77\u201384.","journal-title":"Ophthalmol Glaucoma"},{"issue":"11","key":"1493_CR57","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.9.11.23","volume":"9","author":"J Swogger","year":"2020","unstructured":"Swogger J, Conner IP, Rosano M, et al. Injected versus sponge-applied mitomycin C (MMC) during modified trabeculectomy in New Zealand white rabbit model. Transl Vis Sci Technol. 2020;9(11):23.","journal-title":"Transl Vis Sci Technol"},{"issue":"8","key":"1493_CR58","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/IJG.0000000000000720","volume":"26","author":"K Vinod","year":"2017","unstructured":"Vinod K, Gedde SJ, Feuer WJ, et al. Practice preferences for glaucoma surgery: a survey of the American Glaucoma Society. J Glaucoma. 2017;26(8):687\u201393.","journal-title":"J Glaucoma"},{"key":"1493_CR59","first-page":"7419571","volume":"2019","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zhu S, Xu X, Zuo L. In vitro study of combined application of bevacizumab and 5-fluorouracil or bevacizumab and mitomycin C to inhibit scar formation in glaucoma filtration surgery. J Ophthalmol. 2019;2019:7419571.","journal-title":"J Ophthalmol."},{"issue":"1","key":"1493_CR60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1136\/bjophthalmol-2013-303966","volume":"98","author":"E Vandewalle","year":"2014","unstructured":"Vandewalle E, Abeg\u00e3o Pinto L, van Bergen T, et al. Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study. Br J Ophthalmol. 2014;98(1):73\u20138.","journal-title":"Br J Ophthalmol."},{"issue":"6","key":"1493_CR61","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/17425247.2021.1860014","volume":"18","author":"M Figus","year":"2021","unstructured":"Figus M, Agnifili L, Lanzini M, et al. Topical preservative-free ophthalmic treatments: an unmet clinical need. Expert Opin Drug Deliv. 2021;18(6):655\u201372.","journal-title":"Expert Opin Drug Deliv"},{"key":"1493_CR62","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10081642","author":"L Mikalauskiene","year":"2021","unstructured":"Mikalauskiene L, Grzybowski A, Zemaitiene R. Ocular surface changes associated with ophthalmic surgery. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10081642.","journal-title":"J Clin Med"},{"issue":"2","key":"1493_CR63","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s10792-017-0524-4","volume":"38","author":"M Rolando","year":"2018","unstructured":"Rolando M, Cantera E, Mencucci R, Rubino P, Aragona P. The correct diagnosis and therapeutic management of tear dysfunction: recommendations of the P.I.C.A.S.S.O. board. Int Ophthalmol. 2018;38(2):875\u201395.","journal-title":"Int Ophthalmol"},{"issue":"10","key":"1493_CR64","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jfo.2014.06.004","volume":"37","author":"S Doan","year":"2014","unstructured":"Doan S, Chiambaretta F, Baudouin C. Evaluation of an eyelid warming device (Blephasteam) for the management of ocular surface diseases in France: the ESPOIR study. J Franc Ophtalmol. 2014;37(10):763\u201372.","journal-title":"J Franc Ophtalmol."},{"issue":"12","key":"1493_CR65","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.4103\/ijo.IJO_2296_19","volume":"68","author":"B Sharma","year":"2020","unstructured":"Sharma B, Soni D, Saxena H, et al. Impact of corneal refractive surgery on the precorneal tear film. Indian J Ophthalmol. 2020;68(12):2804\u201312.","journal-title":"Indian J Ophthalmol"},{"key":"1493_CR66","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.2147\/OPTH.S388886","volume":"16","author":"G Li","year":"2022","unstructured":"Li G, Akpek EK, Ahmad S. Glaucoma and ocular surface disease: more than meets the eye. Clin Ophthalmol (Auckland, NZ). 2022;16:3641\u20139.","journal-title":"Clin Ophthalmol (Auckland, N.Z.)."},{"issue":"10","key":"1493_CR67","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1007\/s40123-024-01015-9","volume":"13","author":"C-C Sun","year":"2024","unstructured":"Sun C-C, Chan Y-H, Huang P-W, Chen N-N. Evaluation of two artificial tears containing hyaluronic acid for post cataract surgery dry eye disease: a randomized controlled trial. Ophthalmol Ther. 2024;13(10):2615\u201327.","journal-title":"Ophthalmol Ther"},{"key":"1493_CR68","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.2147\/OPTH.S256351","volume":"14","author":"G Jerkins","year":"2020","unstructured":"Jerkins G, Greiner JV, Tong L, et al. A comparison of efficacy and safety of two lipid-based lubricant eye drops for the management of evaporative dry eye disease. Clin Ophthalmol (Auckland, NZ). 2020;14:1665\u201373.","journal-title":"Clin Ophthalmol (Auckland, N.Z.)."},{"key":"1493_CR69","volume":"15","author":"L Jones","year":"2023","unstructured":"Jones L, Maes N, Qidwai U, Ratnarajan G. Impact of minimally invasive glaucoma surgery on the ocular surface and quality of life in patients with glaucoma. Ther Adv Ophthalmol. 2023;15:25158414231152765.","journal-title":"Ther Adv Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01493-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01493-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01493-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:03:42Z","timestamp":1792807422000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01493-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":69,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1493"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01493-z","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]},"assertion":[{"value":"10 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Antoine Labb\u00e9 is a consultant for Laboratoires Th\u00e9a. Andrew J. Tatham is a consultant for, or has received research support from, Alcon, Viatris, and Laboratoires Th\u00e9a. Ingeborg Stalmans has received grant\/research support from Th\u00e9a, Santen, AbbVie, and Heidelberg; has participated in clinical trials for Bausch + Lomb, Omikron, Th\u00e9a, and Santen; has received honoraria and consulting fees from AbbVie, Bausch + Lomb, Omikron, Santen, and Th\u00e9a; and has investments (stock options) in Mona. Christophe Baudouin reports personal fees from Bausch + Lomb, Glaukos, Oculis, and Santen, and grants and personal fees from Horus Pharma, and grants from Laboratoires Th\u00e9a.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}